At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
In Brief
A Phase 3 clinical trial evaluating Deucravacitinib, Placebo, and 1 other intervention for Psoriatic Arthritis. Active but no longer recruiting, targeting 729 participants across 138 sites in 18 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.
Study Details
Timeline
Interventions
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days